VCA Stocks

Traversa Therapeutics, Inc. announced today the completion of a $2 million Series A financing.  Traversa Therapeutics is a La Jolla, California-based biopharmaceutical company engaged in the discovery, development and commercialization of RNAi delivery technologies. The company strives to rapidly advance siRNA platform delivery technologies for use internally and by other pharmaceutical companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa also markets its technology for high throughput RNAi screening applications.  “Traversa is currently being evaluated by several large pharmaceutical companies to treat diseases of the eye and nose, metabolic diseases, cancer and infectious diseases.”